<SEC-DOCUMENT>0001193125-24-153648.txt : 20240604
<SEC-HEADER>0001193125-24-153648.hdr.sgml : 20240604
<ACCEPTANCE-DATETIME>20240604073555
ACCESSION NUMBER:		0001193125-24-153648
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20240603
FILED AS OF DATE:		20240604
DATE AS OF CHANGE:		20240604

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			IMMUTEP Ltd
		CENTRAL INDEX KEY:			0001506184
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			C3
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35428
		FILM NUMBER:		241016085

	BUSINESS ADDRESS:	
		STREET 1:		LEVEL 32, SUITE 32.07 AUSTRALIA SQUARE
		STREET 2:		264 GEORGE STREET
		CITY:			SYDNEY,
		STATE:			C3
		ZIP:			NSW 2000
		BUSINESS PHONE:		612 8315 7003

	MAIL ADDRESS:	
		STREET 1:		LEVEL 32, SUITE 32.07 AUSTRALIA SQUARE
		STREET 2:		264 GEORGE STREET
		CITY:			SYDNEY,
		STATE:			C3
		ZIP:			NSW 2000

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Prima BioMed Ltd
		DATE OF NAME CHANGE:	20101119
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>d641939d6k.htm
<DESCRIPTION>6-K
<TEXT>
<HTML><HEAD>
<TITLE>6-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM 6-K
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>REPORT OF FOREIGN PRIVATE ISSUER </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT TO RULE 13a-16 OR 15d-16 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>UNDER THE SECURITIES EXCHANGE ACT OF 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Date as June 03, 2024 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Commission File Number 001-35428 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>IMMUTEP
LIMITED </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact Name as Specified in its Charter) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>N/A </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Translation of
Registrant&#146;s Name) </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Level 32, Australia Square </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>264 George Street, Sydney </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NSW 2000, Australia </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive office) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether
the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Form 20-F&#8194;&#9746;&#8195;&#8195;&#8195;Form
40-F&#8194;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule
101(b)(1):&#8194;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule
101(b)(7):&#8194;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing
the information to the Commission pursuant to Rule&nbsp;12g3-2(b) under the Securities Exchange Act of 1934. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Yes&#8194;&#9744;&#8195;&#8195;&#8195;No&#8194;&#9746; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If &#147;Yes&#148; is marked, indicated below the file number assigned to the registrant in connection with Rule 12g3-2(b): Not applicable. </P>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT INDEX </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="94%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Exhibit</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Description&nbsp;of&nbsp;Exhibit</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">99.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="d641939dex991.htm">Immutep Announces Clinical Collaboration with MSD to Evaluate Efti in Combination with KEYTRUDA<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> (pembrolizumab) in Pivotal Phase III
Trial</A></TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dated: June 03, 2024 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">IMMUTEP LIMITED</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Marc Voigt</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Marc Voigt</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chief Executive Officer</TD></TR>
</TABLE></DIV>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d641939dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g641939dsp4.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Immutep Announces Clinical Collaboration with MSD to Evaluate Efti in </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Combination with KEYTRUDA<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> (pembrolizumab) in </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pivotal Phase III Trial </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Phase III collaboration will evaluate efti in combination with KEYTRUDA, MSD&#146;s <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> therapy, and standard chemotherapy in first-line <FONT STYLE="white-space:nowrap">non-small</FONT> cell lung cancer (1L NSCLC) </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT STYLE="white-space:nowrap">TACTI-004</FONT> Phase III trial will enrol approximately 750 patients
regardless of <FONT STYLE="white-space:nowrap">PD-L1</FONT> expression in order to address the entire 1L NSCLC market eligible for <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> therapy
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Under the collaboration, Immutep will conduct the registrational
<FONT STYLE="white-space:nowrap">TACTI-004</FONT> Phase III trial and MSD will supply KEYTRUDA </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Immutep retains commercial rights to efti </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Efti in combination with KEYTRUDA with or without chemotherapy has generated compelling efficacy and favourable
safety in 1L NSCLC, one of the most relevant cancer indications with a high unmet medical need, across all levels of <FONT STYLE="white-space:nowrap">PD-L1</FONT> expression (negative, low, and high) </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SYDNEY, AUSTRALIA &#150; 3</B><B></B><B>&nbsp;June, </B><B>2024 &#150;</B><B> </B><U>Immutep Limited</U><B> </B>(ASX: IMM; NASDAQ: IMMP)
(&#147;Immutep&#148; or &#147;the Company&#148;), a clinical-stage biotechnology company developing novel <FONT STYLE="white-space:nowrap">LAG-3</FONT> immunotherapies for cancer and autoimmune disease, today announced that it has entered into a
clinical trial collaboration and supply agreement with MSD (Merck&nbsp;&amp; Co., Inc., Rahway, NJ, USA), through a subsidiary, to evaluate eftilagimod alfa (efti) in combination with MSD&#146;s <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> therapy, KEYTRUDA<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> (pembrolizumab) and chemotherapy for the first-line treatment of metastatic
<FONT STYLE="white-space:nowrap">non-small</FONT> cell lung cancer (NSCLC) in a pivotal Phase III trial. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The potential for efti in combination with
KEYTRUDA and chemotherapy is to set a new standard of care, by strengthening clinical outcomes for responders and broadening the number of patients who respond across the entire NSCLC patient population regardless of
<FONT STYLE="white-space:nowrap">PD-L1</FONT> expression. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">TACTI-004</FONT> (Two ACTive
<FONT STYLE="white-space:nowrap">Immunotherapies-004)</FONT> Registrational Phase III Trial Design </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">TACTI-004</FONT>
will be a 1:1 randomised, double-blind, multinational, controlled clinical study to evaluate Immutep&#146;s efti in combination with KEYTRUDA and standard chemotherapy compared to the
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">standard-of-care</FONT></FONT> combination of KEYTRUDA, chemotherapy and placebo in first-line metastatic NSCLC, regardless of <FONT STYLE="white-space:nowrap">PD-L1</FONT>
expression. In this pivotal <FONT STYLE="white-space:nowrap">PD-L1</FONT> all comer trial, the dual primary endpoints will be progression-free and overall survival with a prespecified futility boundary and a
<FONT STYLE="white-space:nowrap">pre-planned</FONT> interim analysis. The globally conducted study will enrol approximately 750 NSCLC patients (including both squamous and <FONT STYLE="white-space:nowrap">non-squamous</FONT> subtypes). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Building on Encouraging Data from Prior Trials </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;We
are eager to build upon the meaningful impact that immunotherapy has brought to patients with NSCLC, one of the largest cancer indications globally, and look for <FONT STYLE="white-space:nowrap">TACTI-004</FONT> to confirm the clinical benefits that
have been achieved with efti in combination with KEYTRUDA. This collaboration agreement speaks to the strength of the clinical data generated to date from this novel immuno-oncology combination and its future potential. We are thankful for this
significant commitment from MSD,&#148; stated Marc Voigt, CEO of Immutep. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g641939dsp4.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This collaboration follows two previous collaborations for the
<FONT STYLE="white-space:nowrap">TACTI-002</FONT> Phase II and <FONT STYLE="white-space:nowrap">TACTI-003</FONT> Phase IIb trials, which collectively treated over 350 patients. Under the terms of the agreement, Immutep will conduct the
registrational <FONT STYLE="white-space:nowrap">TACTI-004</FONT> study and MSD will supply KEYTRUDA. The agreement enables Immutep and MSD to seek marketing authorisation of the combination and to market their respective compounds with a relevant
label indication. The parties retain the commercial rights to their respective compounds and are free to conduct other clinical studies, either individually or in combination, in any therapeutic area. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The clinical data generated by the innovative immuno-oncology combination of Immutep&#146;s MHC Class&nbsp;II agonist and MSD&#146;s <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> therapy in the <FONT STYLE="white-space:nowrap">TACTI-002</FONT> Phase II trial in first-line NSCLC regardless of <FONT STYLE="white-space:nowrap">PD-L1</FONT>
expression has led to oral presentations at the ASCO, SITC, and ESMO conferences. Efti&#146;s unique activation of dendritic cells (the most potent professional antigen-presenting cells) engages the adaptive and innate immune system to drive a broad
anti-cancer immune response, including proliferation of cytotoxic T cells that complements <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> therapy in first-line NSCLC across all levels of <FONT
STYLE="white-space:nowrap">PD-L1</FONT> expression (negative, low, and high). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notably, over 75% of the patients in both the <FONT
STYLE="white-space:nowrap">TACTI-002</FONT> and <FONT STYLE="white-space:nowrap">INSIGHT-003</FONT> clinical trials had a <FONT STYLE="white-space:nowrap">PD-L1</FONT> Tumor Proportion Score (TPS) of &lt;50%, and both studies have shown strong
efficacy in these patients with low and negative <FONT STYLE="white-space:nowrap">PD-L1</FONT> expression who are typically less responsive to <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> therapy.
Furthermore, the triple combination of efti, KEYTRUDA and carboplatin/pemetrexed in <FONT STYLE="white-space:nowrap">INSIGHT-003</FONT> has been well tolerated. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;KEYTRUDA has revolutionized the treatment landscape in NSCLC and our confidence in efti&#146;s ability to build upon its positive impact on patient
outcomes, and potentially expand the number of responding patients, stems from the compelling data in our <FONT STYLE="white-space:nowrap">TACTI-002</FONT> and <FONT STYLE="white-space:nowrap">INSIGHT-003</FONT> trials. We are excited to confirm the
differentiated efficacy and safety that we have seen to date in NSCLC via efti&#146;s first pivotal Phase III study and <FONT STYLE="white-space:nowrap">TACTI-004&#146;s</FONT> robust randomized, double-blind trial design,&#148; added Christian
Mueller, Immutep&#146;s SVP, Regulatory and Strategy. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Lung cancer is the second most common cancer. <FONT STYLE="white-space:nowrap">Non-small</FONT>
cell lung cancer accounts for approximately <FONT STYLE="white-space:nowrap">80-85%</FONT> of all lung cancers, impacting an estimated 1.87&nbsp;million people annually, and is the highest cause of death among all cancers<SUP
STYLE="font-size:75%; vertical-align:top"><FONT STYLE="white-space:nowrap">1-3</FONT></SUP>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">KEYTRUDA<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> is a registered trademark of Merck Sharp&nbsp;&amp; Dohme LLC, a subsidiary of
Merck&nbsp;&amp; Co., Inc., Rahway, NJ, USA. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Eftilagimod Alfa (Efti) </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Efti is Immutep&#146;s proprietary soluble <FONT STYLE="white-space:nowrap">LAG-3</FONT> protein and MHC Class&nbsp;II agonist that stimulates both innate and
adaptive immunity for the treatment of cancer. As a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class</FONT></FONT> antigen presenting cell (APC) activator, efti binds to MHC (major histocompatibility complex)
Class&nbsp;II molecules on APC leading to activation and proliferation of CD8+ cytotoxic T cells, CD4+ helper T cells, dendritic cells, NK cells, and monocytes. It also upregulates the expression of key biological molecules like IFN-<FONT
STYLE="font-family:Times New Roman; font-size:8pt">&#978</FONT><FONT STYLE="font-family:Times New Roman; font-size:10pt"> and CXCL10 that further boost the immune system&#146;s ability to fight cancer. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Efti is under evaluation for a variety of solid tumours including <FONT STYLE="white-space:nowrap">non-small</FONT> cell lung cancer (NSCLC), head and neck
squamous cell carcinoma (HNSCC), and metastatic breast cancer. Its favourable safety profile enables various combinations, including with <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-[L]1</FONT></FONT> immunotherapy
and/or chemotherapy. Efti has received Fast Track designation in first line HNSCC and in first line NSCLC from the United States Food and Drug Administration (FDA). </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g641939dsp4.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Immutep </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Immutep is a clinical-stage biotechnology company developing novel <FONT STYLE="white-space:nowrap">LAG-3</FONT> immunotherapy for cancer and autoimmune
disease. We are pioneers in the understanding and advancement of therapeutics related to Lymphocyte Activation <FONT STYLE="white-space:nowrap">Gene-3</FONT> <FONT STYLE="white-space:nowrap">(LAG-3),</FONT> and our diversified product portfolio
harnesses its unique ability to stimulate or suppress the immune response. Immutep is dedicated to leveraging its expertise to bring innovative treatment options to patients in need and to maximise value for shareholders. For more information,
please visit <U>www.immutep.com</U>. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Australian Investors/Media: </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Catherine Strong, Morrow Sodali </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+61 (0)406 759 268;
<U>c.strong@morrowsodali.com</U> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>U.S. Media: </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Chris
Basta, VP, Investor Relations and Corporate Communications </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+1 (631) 318 4000; <U>chris.basta@immutep.com</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1&nbsp;The Global Cancer Observatory,&nbsp;Lung Cancer Fact Sheet </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">2&nbsp;American Cancer Society,&nbsp;About Lung Cancer </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">3&nbsp;CDC,&nbsp;Lung Cancer Statistics </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This announcement was
authorised for release by the Board of Immutep Limited. </P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Immutep Limited</B>,
Level&nbsp;32, Australia Square, 264 George Street, Sydney NSW 2000, Australia </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ABN: 90 009 237 889 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g641939dsp4.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g641939dsp4.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M P$  A$#$0 _ /W\H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@!"0OMVHV#;TB12W$%O&\LTT<,42EWDE81QHBC)9G; 50!DDG@4I-07O/
ME2[D2G"G!5)R48=&W9'!2?%?X<17'V5O&GASS%;8=NIV[1*0<'=.K&)<>[]J
MYUC,+?E5:-UTN>?+.<KA+DEC:49+I=_Y'>6]U;7<,4]K/#<031K+#-!(LL4L
M; %)(Y$)5T(((8$@@C%=$91DKQ::Z69Z$)PG",Z<E*$E>,HNZMY-$X/^?I3V
M\K%KRV"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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MT_C7+\*7XZ$E PH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M?0?H!7UB^ST21^PQT\MA]44% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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MO=W]VQBMK=99H[>)I),?*&FEC0>[CUK6UOD=O5QZQ5VO(Q_"WC[P9XV^V_\
M")>)-+U_^S?L_P!N_LVX$_V7[5YWV;SL ;/,^SS[?7RFH L>*/&GA7P5:V][
MXKU[3M M+NX^RVL^HS>1'-<"-YO)C8@[I!%&[8'930!/X>\3^'O%VFC5O#6K
M6>M:8TTMNM[82>;;F>W*B6+S  -Z%ER/>@#\D_A%XLMM)^/VB:[XLUUK;3+#
M6/$@N=2U>\FD@M5ETK6+: /-.[>6AFDBC';+**-O(-O(_3G3OC9\)]3O;+3-
M/\?>'+O4+^YM[*RM(+T/-<W=U*D%O;Q*%^:625T11W+ 4 >I%@HSG 'Z8X_2
M@#R;Q1\=/A+X,O'TW7_&^E6VHPMY<]C9I>:O=VT@.#'=0:/:W+6D@P<I-L;V
MY&0#?\'?$WP%X_C=O"'BC2]:DA3S)K2"22#4((R0!)/IMY'%=PQY( =X54G@
M'- '5:GJ^E:'93:EK.I6&D:=;A3/?ZE=P6-G &8(GFW-RZ1Q[G95&YADD <F
M@#R&_P#VCO@EILIBN/B%H\A4XS80:GJL?MMETNPN$8$="&.>U '1>%OC'\+_
M !K<I8^&/&NBZC?2<16#2RV%_,1G(@L=2AMYYV !)$<;$ 4;?(-K6TL+XX^&
M>C>-'M-2+SZ5XCTQHI-)\1:<(Q>VC0R/+"LJ2-LO+99&+"-QD%GV,OF-GEQ&
M$IXCWN;V=2.TK7^5K'E9CE&'Q[C4THXBDU*%1*[373T9\XZG^S%XQU/5;J^N
M_%^D7;W=PTUQ?W%K=QWDC/\ >D:VC#1[N!\HG XQFO)ED]:4N:>(4DMDE;3]
M#Y2MP?BZ]>=66/495?B;CT]#WWX;_!_PY\.X_M%JLFI:Y+"8;G6;M5$P5BI>
M&R@1BEG;%E^Z-TC<!Y'P /5P^"HX=*RO-*S?]>A])E&08')X)TX.OBK6E6D^
MC:;23>BND]NFYZX!MQVQQ]*Z]O*Q[G6]K6Z"T % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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MAI]W$TNE7ERS?,]WM@NH)';+.;02.2\C4?H'Z'U'0 4 % !0 4 % !0 4 %
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M:  J#VZ?IB@ "A>@QC^G% "T % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!#Y\/\
MST48]P,8J>>"=N9772YE[>C_ ,_H*W]Y!Y\/_/1?S%/FC_,OO0>WH?\ /Z'_
M ($@\^'_ )Z+^8HYH_S+[T'MZ'_/Z'_@2#SX?^>B_F*.:/\ ,OO0>WH?\_H?
M^!(//A_YZ+^8HYH_S+[T'MZ'_/Z'_@2#SX?^>B_F*.:/\R^]![>A_P _H?\
M@2#SX?\ GHOYBCFC_,OO0>WH?\_H?^!(//A_YZ+^8HYH_P R^]![>A_S^A_X
M$@\^'_GHOYBCFC_,OO0>WH?\_H?^!(//A_YZ+^8HYH_S+[T'MZ'_ #^A_P"!
M(//A_P">B_F*.:/\R^]![>A_S^A_X$@\^'_GHOYBCFC_ #+[T'MZ'_/Z'_@2
M#SX?^>B_F*.:/\R^]![>A_S^A_X$@\^'_GHOYBCFC_,OO0>WH?\ /Z'_ ($@
M\^'_ )Z+^8HYH_S+[T'MZ'_/Z'_@2#SX?^>B_F*.:/\ ,OO0>WH?\_H?^!(/
M/A_YZ+^8HYH_S+[T'MZ'_/Z'_@2#SX?^>B_F*.:/\R^]![>A_P _H?\ @2#S
MX?\ GHOYBCFC_,OO0>WH?\_H?^!(//A_YZ+^8HYH_P R^]![>A_S^A_X$@\^
M'_GHOYBCFC_,OO0>WH?\_H?^!(//A_YZ+^8HYH_S+[T'MZ'_ #^A_P"!(//A
M_P">B_F*.:/\R^]![>A_S^A_X$@\^'_GHOYBCFC_ #+[T'MZ'_/Z'_@2#SX?
M^>B_F*.:/\R^]![>A_S^A_X$@\^'_GHOYBCFC_,OO0>WH?\ /Z'_ ($@\^'_
M )Z+^8HYH_S+[T'MZ'_/Z'_@2#SX?^>B_F*.:/\ ,OO0>WH?\_H?^!(//A_Y
MZ+^8HYH_S+[T'MZ'_/Z'_@2#SX?^>B_F*.:/\R^]![>A_P _H?\ @2#SX?\
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M//A_YZ+^8HYH_P R^]![>A_S^A_X$@-Q"/\ EHOY@T<T?YE]XGB*"_Y>Q_\
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M^2K]S#^R<_\ ^@?$_<_\P_X5A\3O^A1\2_\ @'/_ (T?5L=_)5^YA_9.?_\
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MOW,/[)S_ /Z!\3]S_P P_P"%8?$[_H4?$O\ X!S_ .-'U;'?R5?N8?V3G_\
MT#XG[G_F'_"L/B=_T*/B7_P#G_QH^K8[^2K]S#^R<_\ ^@?$_<_\P_X5A\3O
M^A1\2_\ @'/_ (T?5L=_)5^YA_9.?_\ 0/B?N?\ F'_"L/B=_P!"CXE_\ Y_
M\:/JV._DJ_<P_LG/_P#H'Q/W/_,/^%8?$[_H4?$O_@'/_C1]6QW\E7[F']DY
M_P#] ^)^Y_YA_P *P^)W_0H^)?\ P#G_ ,:/JV._DJ_<P_LG/_\ H'Q/W/\
MS#_A6'Q._P"A1\2_^ <_^-'U;'?R5?N8?V3G_P#T#XG[G_F'_"L/B=_T*/B7
M_P  Y_\ &CZMCOY*OW,/[)S_ /Z!\3]S_P P_P"%8?$[_H4?$O\ X!S_ .-'
MU;'?R5?N8?V3G_\ T#XG[G_F'_"L/B=_T*/B7_P#G_QH^K8[^2K]S#^R<_\
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M^%8?$[_H4?$O_@'/_C1]6QW\E7[F']DY_P#] ^)^Y_YA_P *P^)W_0H^)?\
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M<_\ ^@?$_<_\P_X5A\3O^A1\2_\ @'/_ (T?5L=_)5^YA_9.?_\ 0/B?N?\
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M'_"L/B=_T*/B7_P#G_QH^K8[^2K]S#^R<_\ ^@?$_<_\P_X5A\3O^A1\2_\
M@'/_ (T?5L=_)5^YA_9.?_\ 0/B?N?\ F'_"L/B=_P!"CXE_\ Y_\:/JV._D
MJ_<P_LG/_P#H'Q/W/_,/^%8?$[_H4?$O_@'/_C1]6QW\E7[F']DY_P#] ^)^
MY_YA_P *P^)W_0H^)?\ P#G_ ,:/JV._DJ_<P_LG/_\ H'Q/W/\ S#_A6'Q.
M_P"A1\2_^ <_^-'U;'?R5?N8?V3G_P#T#XG[G_F'_"L/B=_T*/B7_P  Y_\
M&CZMCOY*OW,/[)S_ /Z!\3]S_P P_P"%8?$[_H4?$O\ X!S_ .-'U;'?R5?N
M8?V3G_\ T#XG[G_F'_"L/B=_T*/B7_P#G_QH^K8[^2K]S#^R<_\ ^@?$_<_\
MP_X5A\3O^A1\2_\ @'/_ (T?5L=_)5^YA_9.?_\ 0/B?N?\ F'_"L/B=_P!"
MCXE_\ Y_\:/JV._DJ_<P_LG/_P#H'Q/W/_,/^%8?$[_H4?$O_@'/_C1]6QW\
ME7[F']DY_P#] ^)^Y_YA_P *P^)W_0H^)?\ P#G_ ,:/JV._DJ_<P_LG/_\
MH'Q/W/\ S#_A6'Q._P"A1\2_^ <_^-'U;'?R5?N8?V3G_P#T#XG[G_F'_"L/
MB=_T*/B7_P  Y_\ &CZMCOY*OW,/[)S_ /Z!\3]S_P P_P"%8?$[_H4?$O\
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CX8'H* YGW?WA@>@H#F?=_>&!Z#CVZ8J9;>A4-79ZI=&?_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
